HLX13 clinical trials
Also written HLX13.
How each study uses HLX13 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HLX13 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HLX13
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test HLX13, phase 3 first.
- Jun 2027A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaPhase 3 · Shanghai Henlius Biotech
- Dec 2026Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaPhase 1 · Shanghai Henlius Biotech
Studies
Open first, then newest update. How each study uses HLX13 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 1Shanghai Henlius BiotechNCT07176650Written as HLX13Report a problem
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06841185Written as HLX13Report a problem
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingPhase 1Shanghai Henlius BiotechNCT06159101Written as HLX13Report a problem
Tested on its own · 2 — no other medicine in its arm
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06841185Written as HLX13Report a problem
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingPhase 1Shanghai Henlius BiotechNCT06159101Written as HLX13Report a problem
Tested with established drugs · 1 — they are given beside it
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 1Shanghai Henlius BiotechNCT07176650Written as HLX13Report a problem